Comparative in silico design and validation of GPS™ CoVID-19 dtec-RT-qPCR test

Area of Science:

• Molecular Biology
• Virology
• Infectious Diseases

Background:

• The COVID-19 pandemic necessitates accurate and reliable diagnostic tools.
• Early reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) methods for SARS-CoV-2 detection sometimes lacked sufficient exclusivity.
• Distinguishing SARS-CoV-2 from other coronaviruses is critical to prevent misdiagnosis.

Purpose of the Study:

• To provide a fully validated, ready-to-use RT-qPCR method for SARS-CoV-2 detection.
• To achieve higher exclusivity compared to previously published RT-qPCR designs.
• To ensure accurate and reliable COVID-19 diagnostics.

Main Methods:

• The GPS™ CoVID-19 dtec-RT-qPCR test was developed and validated.
• Specificity was assessed through sequence alignment analysis and comparison with other RT-qPCR designs.
• Validation followed stringent international standards (UNE/EN ISO 17025:2005 and ISO/IEC 15189:2012).
• Diagnostic validation was performed by two independent reference laboratories: Instituto de Salud Carlos III and Public Health England.
• The test received CE-IVD marking.

Main Results:

• The GPS™ design demonstrated superior exclusivity for SARS-CoV-2.
• The test passed all validation parameters with strict acceptance criteria.
• Results from reference laboratories showed 100% correlation with established reference methods.
• The test achieved 100% diagnostic sensitivity and specificity.
• The GPS™ CoVID-19 dtec-RT-qPCR test is available worldwide.

Conclusions:

• The CE-IVD GPS™ CoVID-19 dtec-RT-qPCR test is highly exclusive for SARS-CoV-2 detection.
• This validated method is crucial for accurate COVID-19 diagnosis, preventing false positives from related coronaviruses.
• The study highlights successful technology transfer for a critical pandemic diagnostic tool.